{"product_id":"cholesterol-vs-stress-one-doctors-case-that-stress-not-cholesterol-is-the-real-heart-disease-driver","title":"Cholesterol vs. Stress: One Doctor's Case That Stress—Not Cholesterol—Is the Real Heart Disease Driver","description":"\u003cp\u003eThe widely held belief that cholesterol causes coronary heart disease (CHD) is not supported by evidence, according to this provocative invited article from the \u003cem\u003eScandinavian Cardiovascular Journal\u003c\/em\u003e. Instead, the author argues that stress—not cholesterol or dietary fat—is a far more important and scientifically grounded contributor to heart attacks and atherosclerosis. The article walks through decades of famous studies, including the Seven Countries Study, the Framingham Heart Study, and the MRFIT trial, to explain how the cholesterol hypothesis took hold despite contradictory findings, and why stress deserves much more attention from doctors and patients.\u003c\/p\u003e\n\n\u003ch1\u003eCholesterol vs. Stress: One Doctor's Case That Stress—Not Cholesterol—Is the Real Heart Disease Driver\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n\u003cli\u003e\u003ca href=\"#intro\"\u003eIntroduction: Why This Debate Matters\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#history\"\u003eA Brief History of the Cholesterol Hypothesis\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#keys\"\u003eAncel Keys' Seven Countries Study and the Low-Fat Campaign\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#framingham\"\u003eThe Framingham Heart Study: Uncomfortable Findings\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#mrfit\"\u003eMRFIT: The Largest Cholesterol Trial's Unreported Failures\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#cppt\"\u003eThe Coronary Primary Prevention Trial and the NIH Consensus\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#relative-risk\"\u003eRelative Risk Versus Absolute Risk: What the Numbers Really Mean\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#monica\"\u003eThe MONICA Project: A Global Reality Check\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#stress\"\u003eAssociation, Risk Factors, and Stress: What Matters?\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications and Patient Recommendations\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations and Context\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn the Framingham study, half of heart attacks occurred in people with normal or low cholesterol, and falling cholesterol levels were linked to higher mortality.\u003c\/li\u003e\n\u003cli\u003eThe MONICA project, covering 21 countries over 10 years, found no correlation between fat consumption or cholesterol levels and cardiac death rates.\u003c\/li\u003e\n\u003cli\u003eIn the MRFIT trial, aggressive diet and lifestyle changes did not significantly reduce total death rates, with increases seen in hemorrhagic stroke, cancer, suicide, and accidents.\u003c\/li\u003e\n\u003cli\u003eThe CPPT cholesterol-lowering trial showed reduced relative risk but no total mortality benefit; the absolute risk reduction was only 1.4%, meaning a number needed to treat of 71.\u003c\/li\u003e\n\u003cli\u003eStress may promote inflammation, clotting, and heart muscle damage, and Type A behavior is as significant a risk factor as high cholesterol, hypertension, and smoking.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"intro\"\u003eIntroduction: Why This Debate Matters\u003c\/h2\u003e\n\u003cp\u003eThe article opens with a quote from philosopher Arthur Schopenhauer: \u003cem\u003e\"All truth passes through three stages. First, it is ridiculed, second, it is violently opposed, and third, it is accepted as self-evident.\"\u003c\/em\u003e The author, Dr. Paul J. Rosch, a professor of medicine and psychiatry at New York Medical College and president of The American Institute of Stress, believes that the cholesterol theory of heart disease is undergoing the second and third of those stages. He argues that the cholesterol campaign has caused immeasurable harm to public health, quality of life, the economy, and medical research, and that public health officials, physicians, and patients deserve to know what he calls proof that the campaign is \"misguided, malicious and malignant.\"\u003c\/p\u003e\n\u003cp\u003eThis is a strong opinion. But the article is not a random blog post. It is a peer-reviewed, invited article published in a mainstream cardiovascular journal. It challenges a deeply entrenched medical doctrine. Understanding the arguments and evidence behind this challenge can help patients ask better questions about their own heart health, cholesterol numbers, and stress.\u003c\/p\u003e\n\n\u003ch2 id=\"history\"\u003eA Brief History of the Cholesterol Hypothesis\u003c\/h2\u003e\n\u003cp\u003eThe story begins in 1856, when the German pathologist Rudolf Virchow first described the presence of cholesterol in human atheroma—the fatty, hardened plaque that builds up inside arteries. Virchow called the process \u003cstrong\u003eendarteritis deformans\u003c\/strong\u003e, emphasizing that it was an inflammatory process that injured the inner lining (the intima) of the arteries. He wrote that the process \"has arisen out of irritation of the parts stimulating them to new, formative actions,\" and therefore belonged under the idea of inflammation.\u003c\/p\u003e\n\u003cp\u003eA few decades later, Sir William Osler, the famous Canadian physician, also attributed atherosclerosis to \"the normal wear and tear of life, the acute infections, the intoxications [including smoking, diabetes mellitus, obesity], and those combinations of circumstances which keep the blood tension high.\" Notice what is missing from Osler's list: fatty foods and cholesterol.\u003c\/p\u003e\n\u003cp\u003eThat changed after a series of animal experiments in the early 1900s. In 1909, a researcher named Ignatowski fed rabbits large amounts of meat, eggs, and milk. He reported that this produced macroscopic (visible) lesions in the rabbits' arteries that resembled human atherosclerosis. The following year, Windaus showed that these intimal deposits contained \u003cstrong\u003esix times as much free cholesterol and twenty times as much esterified cholesterol\u003c\/strong\u003e compared to a normal arterial wall.\u003c\/p\u003e\n\u003cp\u003eThen came Anitschkow, who demonstrated in 1913 that the same vascular lesions could be produced by feeding rabbits cholesterol purified from egg yolks for two or more months. The earliest fat-laden lesions appeared in the aortic arch and then spread downward. But there were major problems with using rabbits as models for human heart disease. Rabbits do not naturally eat meat or eggs. More importantly, the deposits in rabbits did not have the microscopic inflammatory features that are characteristic of obstructive atherosclerotic plaque in humans. Also, attempts to reproduce atheromatous lesions in other experimental animals failed completely.\u003c\/p\u003e\n\u003cp\u003eThere was another conceptual problem: cholesterol is a large, inert molecule. It was hard to understand how it could squeeze into the lining of a coronary artery and cause inflammation. As Virchow had originally stressed, the author notes, human atherosclerotic plaque is a response to inflammation—\u003cstrong\u003enot\u003c\/strong\u003e the simple deposition of cholesterol as commonly claimed.\u003c\/p\u003e\n\n\u003ch2 id=\"keys\"\u003eAncel Keys' Seven Countries Study and the Low-Fat Campaign\u003c\/h2\u003e\n\u003cp\u003eFew physicians or researchers in the United States initially knew about Anitschkow or his hypothesis that increased cholesterol intake raised blood cholesterol, which then caused atherosclerosis. Nor was there much interest. Before the 1920s, heart disease caused less than 10% of all deaths in the USA. But by the 1950s, this had escalated to over 30%. Something had clearly changed, and Ancel Keys, a physiologist who chaired the first conference of the Food and Agriculture Organization of the UN in Rome in 1951, was curious about the rise in heart attacks among middle-aged men.\u003c\/p\u003e\n\u003cp\u003eKeys visited Naples, Italy, where he confirmed that there were almost no coronary heart disease patients under the age of 60, except among a small class of wealthy people who ate meat every day. The general population ate meat only once a week or less and primarily lived on pasta, fruits, and vegetables. He also found that average cholesterol levels were low except in the upper class. He concluded there was an association between a high-fat diet, serum cholesterol, and coronary heart disease—just as Anitschkow had proposed.\u003c\/p\u003e\n\u003cp\u003eKeys then launched his famous \u003cstrong\u003eSeven Countries Study\u003c\/strong\u003e, which tracked healthy middle-aged men in seven countries. He reported a remarkable straight-line relationship between saturated fat consumption, serum cholesterol, and deaths from coronary disease. In East Finland, where serum cholesterol averaged over 260 mg\/dL, there were about 70 fatal heart attacks per 1,000 men over a 10-year period. In Japan, by contrast, there were fewer than 5 such deaths, and the average cholesterol was about 160 mg\/dL. Saturated fats contributed over 20% of total daily calories in Finnish men—almost ten times higher than the 2.5% seen in Japanese men. Keys concluded that the risk of fatal heart attacks was proportional to blood cholesterol level, which in turn was proportional to saturated fat intake.\u003c\/p\u003e\n\u003cp\u003eBut there was a serious problem: Keys had data from 22 countries, yet he included only 7 in his analysis. Skeptics accused him of \"cherry picking\" countries to prove his theory. The statistician Russell H. Smith, who later reviewed over 2,000 references on dietary cholesterol and health, wrote that the dietary assessment methodology in the Seven Countries Study was \"highly inconsistent across cohorts and thoroughly suspect.\" Smith said it was \"almost inconceivable that the Seven Countries study was performed with such scientific abandon\" and that the diet-CHD relationship reported \"cannot be taken seriously by the objective and critical scientist.\"\u003c\/p\u003e\n\u003cp\u003eEven Keys himself later admitted, years after his research made him famous, that \"there's no connection whatsoever between cholesterol in food and cholesterol in blood. And we've known that all along. Cholesterol in the diet doesn't matter at all unless you happen to be a chicken or a rabbit.\" This admission came after an experiment in which he fed middle-aged men a very high cholesterol diet and found their blood cholesterol was no different from a control group that consumed less than half as much.\u003c\/p\u003e\n\n\u003ch2 id=\"framingham\"\u003eThe Framingham Heart Study: Uncomfortable Findings\u003c\/h2\u003e\n\u003cp\u003eThe Framingham project began in 1950, initiated by the National Institutes of Health (NIH) in Framingham, Massachusetts. It remains one of the most influential epidemiological studies in heart disease research. The study allegedly provided the first \"solid evidence\" that people with high cholesterol were more likely to have heart attacks and that smoking and hypertension also increased risk. But the author argues that the Framingham data were far less supportive than often claimed.\u003c\/p\u003e\n\u003cp\u003eWilliam Kannel, the director of the Framingham Study during the 1960s, told the press that Framingham essentially proved cholesterol was a powerful predictor of CHD. However, the study data showed that \u003cstrong\u003ehalf of heart attacks occurred in people with normal or even low cholesterol\u003c\/strong\u003e. A dietary analysis conducted in the 1950s found that Framingham participants had widely varying cholesterol levels, and the researchers concluded that \"something explains this interindividual variation but it is not diet.\" That finding was never published.\u003c\/p\u003e\n\u003cp\u003eLater analyses made things even more uncomfortable for the cholesterol hypothesis. A direct association was reported between falling cholesterol levels over the first 14 years of the study and increased mortality rates over the following 18 years. A 30-year follow-up in 1987 stated that the \"most important overall finding is the emergence of the total cholesterol as a risk factor of CHD in the elderly\"—but no data were presented to support that claim. In fact, for men above the age of 47, those with low cholesterol had mortality rates greater than those with high cholesterol. Also, men whose cholesterol decreased spontaneously over 30 years were at greater risk of dying from heart disease than those whose cholesterol increased. The study found that \u003cstrong\u003e\"for each 1% drop in cholesterol there was an 11% increase in coronary and total mortality.\"\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDespite this, the study was cited in a joint American Heart Association–NIH publication called \u003cem\u003eThe Cholesterol Facts\u003c\/em\u003e as proof that a 1% reduction in cholesterol corresponds to a 2% reduction in CHD risk. And in a 1992 article in the \u003cem\u003eArchives of Internal Medicine\u003c\/em\u003e, Dr. William Castelli, then director of the Framingham Study, wrote: \"In Framingham, Mass, the more saturated fat one ate, the more cholesterol one ate, the more calories one ate, the lower the person's serum cholesterol.\" That remarkable statement directly contradicted the story told by the cholesterol campaign.\u003c\/p\u003e\n\n\u003ch2 id=\"mrfit\"\u003eMRFIT: The Largest Cholesterol Trial's Unreported Failures\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eMRFIT\u003c\/strong\u003e (Multiple Risk Factor Intervention Trial) was the largest and most serious attempt to prove the links between diet, cholesterol, and heart disease using the Framingham risk factors. Between 1973 and 1976, researchers screened over 350,000 men who were considered at high risk based on elevated cholesterol, hypertension, and cigarette smoking. From this pool, they selected 12,866 healthy men aged 35 to 57 with no history or evidence of heart disease. These men were randomly assigned to either an intervention group or a control group receiving usual care.\u003c\/p\u003e\n\u003cp\u003eThe intervention group received aggressive treatment: cholesterol consumption was cut by 42%, saturated fat consumption by 28%, and total calories by 21%. Hypertension was reduced with medication, and smoking was curtailed. After ten years, the men who adhered to the dietary fat restriction had slightly lower coronary heart disease death rates. But this small benefit was far outweighed by significantly increased total death rates, especially from hemorrhagic stroke, cancer, suicide, accidents, and violence. The intervention group—even with additional risk factors like hypertension and smoking also reduced—had mortality rates that were not significantly different from the usual care controls. The highest death rates were seen in hypertensives treated with diuretics, a common blood pressure medication at the time.\u003c\/p\u003e\n\u003cp\u003eThe published report emphasized the relationship between cholesterol and mortality using a figure (Figure 1) that showed a smooth curve of rising relative risk. But the author notes that this graph was designed to imply a causal relationship, with no data given for absolute risk. The negative findings—increased total deaths, no survival benefit—were given little attention.\u003c\/p\u003e\n\n\u003ch2 id=\"cppt\"\u003eThe Coronary Primary Prevention Trial and the NIH Consensus\u003c\/h2\u003e\n\u003cp\u003eThe next major event came in 1984 with the Lipid Research Clinics' \u003cstrong\u003eCoronary Primary Prevention Trial (CPPT)\u003c\/strong\u003e. This trial included men aged 35 to 59 with very elevated cholesterol levels. They were placed on a low-cholesterol, low-saturated-fat diet and then divided into two groups: one took cholestyramine, a bile acid binding resin that lowers cholesterol, and the other took a placebo. The study allegedly showed that cholestyramine might reduce major coronary events in half of all men with high cholesterol.\u003c\/p\u003e\n\u003cp\u003eBased on this, the 1984 NIH Consensus Conference on Lowering Blood Cholesterol to Prevent Heart Disease declared that lowering blood cholesterol should be a public health goal for everyone. Its major conclusion, published in the \u003cem\u003eJournal of the American Medical Association\u003c\/em\u003e, stated: \"It has been established beyond a reasonable doubt that lowering definitely elevated blood cholesterol levels (specifically, blood levels of low density [LDL] cholesterol) will reduce the risk of heart attacks caused by coronary heart disease.\" The NIH also created the National Cholesterol Education Program to teach physicians and patients how to diagnose and treat high cholesterol. Doctors received kits describing the advantages of cholesterol-lowering drugs, the benefits of a low-fat diet, the need to replace butter with margarine, and the need to measure cholesterol periodically in everyone.\u003c\/p\u003e\n\u003cp\u003eBut the trial had serious flaws. First, many men stopped taking cholestyramine almost immediately, and very few could tolerate the full daily dose of 24 grams. Although there were fewer heart attack deaths, there was \u003cstrong\u003eno decrease in total mortality\u003c\/strong\u003e, especially from accidents, homicide, suicide, and cancer. Second, the trial included only men aged 35 to 59 with extremely high cholesterol. There was no evidence that lowering cholesterol in women or in men without high cholesterol would provide any benefit or would be safe. Third, as George Mann, a professor of biochemistry at Vanderbilt and an early Framingham researcher, angrily stated: \"They have held repeated press conferences bragging about this cataclysmic breakthrough which the study directors claim shows that lowering cholesterol lowers the frequency of coronary disease. They have manipulated the data or reached the wrong conclusions... The managers at NIH have used Madison Avenue hype to sell this failed trial in the way the media people sell an underarm deodorant.\"\u003c\/p\u003e\n\u003cp\u003eThe media blitz was enormous. One cardiology journal's lead article was titled \"The Lipid Hypothesis Is Proven,\" and the cover of \u003cem\u003ePostgraduate Medicine\u003c\/em\u003e proclaimed \"Coronary Disease Prevention: Proof of the anticholesterol pudding.\"\u003c\/p\u003e\n\n\u003ch2 id=\"relative-risk\"\u003eRelative Risk Versus Absolute Risk: What the Numbers Really Mean\u003c\/h2\u003e\n\u003cp\u003eThe CPPT also introduced a statistic trick that the author says is still widely used today. As shown in Figure 2 of the article, lowering LDL cholesterol was claimed to cut coronary disease risk dramatically. But the benefits were expressed in terms of \u003cstrong\u003erelative risk\u003c\/strong\u003e, not \u003cstrong\u003eabsolute risk\u003c\/strong\u003e. Relative risk sounds impressive because it compares the percentage of events in two groups using a ratio. Absolute risk uses the raw numbers—the actual difference between groups.\u003c\/p\u003e\n\u003cp\u003eThe author gives a clear example using statins. A study might show that over five years, patients taking a statin had 34% fewer heart attacks than patients taking a placebo. That sounds wonderful. But look at the raw numbers: 2.7% of patients on the statin had a heart attack, compared to 4.1% on placebo. The \u003cstrong\u003eabsolute risk reduction is only 1.4%\u003c\/strong\u003e. In other words, if 71 people take the statin every day for five years, it will prevent one person from having a heart attack—but you have no idea if that person will be you. This is called the \u003cstrong\u003enumber needed to treat (NNT)\u003c\/strong\u003e of 71.\u003c\/p\u003e\n\u003cp\u003eThe author stresses that absolute risk reduction and NNT data are rarely given in advertisements or even in many doctor-patient conversations. Statin ads always refer to reducing risk without specifying that it's relative risk. In some countries, the law requires a disclaimer stating that the drug has not been shown to prevent heart attacks.\u003c\/p\u003e\n\n\u003ch2 id=\"monica\"\u003eThe MONICA Project: A Global Reality Check\u003c\/h2\u003e\n\u003cp\u003eIn 2000, the World Health Organization published the results of \u003cstrong\u003eMONICA\u003c\/strong\u003e (Monitoring of Trends and Determinants in Cardiovascular Disease), a massive cardiovascular epidemiological study that assessed 21 countries over 10 years. The results failed to find any correlation or connection between heart attacks and fat consumption or cholesterol levels. This was a major blow to the cholesterol hypothesis.\u003c\/p\u003e\n\u003cp\u003eThe data were striking:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAll of the countries in the top eight for saturated fat consumption actually had lower cardiac mortality rates than all of the eight countries that consumed the least fat.\u003c\/li\u003e\n\u003cli\u003eFrance consumed three times as much saturated fat as Azerbaijan, but had one-eighth the rate of heart disease deaths.\u003c\/li\u003e\n\u003cli\u003eThe heart disease death rate in Finland was four times higher than in Switzerland, even though the amount of fat consumed in the two countries was exactly the same.\u003c\/li\u003e\n\u003cli\u003eThere was also no correlation between the classic Framingham risk factors—cholesterol, smoking, and hypertension—and cardiac deaths in the MONICA data.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese findings, the author notes, have never been adequately explained by cholesterol proponents.\u003c\/p\u003e\n\n\u003ch2 id=\"stress\"\u003eAssociation, Risk Factors, and Stress: What Matters?\u003c\/h2\u003e\n\u003cp\u003eThe author lists many so-called heart attack risk factors: a deep earlobe crease, arcus senilis (a gray ring around the cornea), premature gray hair or vertex baldness, carotid and peripheral vascular disease, living in Glasgow or Eastern Finland, a high saturated fat diet, diabetes, having a pot belly, elevated hemoglobin, excess vitamin D, and deficiencies of copper, magnesium, or selenium. But these are merely \u003cstrong\u003emarkers\u003c\/strong\u003e—they show some statistical association with heart attacks. In many cases they simply reflect a common genetic predisposition. Eliminating or correcting them does not reduce heart disease deaths. The same, the author argues, holds true for the standard Framingham risk factors of cholesterol, hypertension, and smoking, as demonstrated in the MRFIT study.\u003c\/p\u003e\n\u003cp\u003eThe author states flatly: \u003cstrong\u003eThere is no single cause of CHD.\u003c\/strong\u003e Coronary atherosclerosis is a multifactorial disorder most likely due to subclinical (low-level) inflammation that can be caused by many factors, including chronic infection, homocysteine, increased clotting tendency, and other irritants. And stress is a common denominator for many of these factors. According to the article, stress can:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIncrease homocysteine, C-reactive protein, and fibrinogen—all of which promote inflammation or coagulation\u003c\/li\u003e\n\u003cli\u003eCause coronary vasoconstriction, spasm, and increased platelet adhesiveness and aggregation, which favors the formation of blood clots\u003c\/li\u003e\n\u003cli\u003eCause increased visceral fat deposits that contribute to insulin resistance, diabetes, elevated triglycerides, and other manifestations of metabolic syndrome\u003c\/li\u003e\n\u003cli\u003eProduce myocardial necrosis (death of heart muscle cells) in the absence of coronary blockage, through increased secretion of catecholamines at nerve endings in the ventricle\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eDepression, anxiety, anger, hostility, major life change events, and especially job stress have all been linked to increased coronary events and deaths in scientific studies. The author points out that \u003cstrong\u003eType A behavior\u003c\/strong\u003e—a pattern of urgency, competitiveness, and hostility—is as significant a \"risk factor\" for heart attacks as elevated cholesterol, hypertension, and smoking. He also notes that stress elevates cholesterol far more than dietary fat intake does, and stress also contributes to smoking and hypertension. In contrast to the cholesterol story, some studies have shown that reducing coronary-prone Type A behavior, depression, hostility, and anger can help lower cardiac morbidity and mortality.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications and Patient Recommendations\u003c\/h2\u003e\n\u003cp\u003eWhat does this mean for patients? Based on the author's argument, you should be very cautious if a doctor tells you that cholesterol alone is the enemy and that simply taking a statin or cutting fat will solve your heart disease risk. The full picture is more complicated. If stress is a major driver of inflammation and heart disease, then reducing chronic stress may be at least as important as lowering cholesterol.\u003c\/p\u003e\n\u003cp\u003eHere are some practical takeaways consistent with the article's message:\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eDon't ignore stress.\u003c\/strong\u003e Chronic stress, job strain, anxiety, anger, and depression are not \"soft\" risk factors. They affect your heart through real biological pathways—inflammation, blood clotting, blood vessel spasm, and more.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAsk your doctor for absolute numbers.\u003c\/strong\u003e Instead of asking \"How much will this statin reduce my risk?\" ask \"What is my absolute risk of a heart attack without it, and what is my absolute risk with it?\" and \"How many people need to take this drug to prevent one heart attack?\"\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBe skeptical of one-variable solutions.\u003c\/strong\u003e Heart disease is multifactorial. Don't obsess over a single number while ignoring stress, sleep, relationships, and other aspects of physical and mental health.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eConsider stress management as heart therapy.\u003c\/strong\u003e Techniques such as mindfulness, cognitive behavioral therapy, exercise, social connectedness, and—where appropriate—professional counseling may lower cardiac risk.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDon't change your medications without talking to your doctor.\u003c\/strong\u003e Despite this article's criticisms, many cardiologists still believe that cholesterol-lowering drugs benefit high-risk patients. The purpose of this article is to inform, not to give individual medical advice. Always discuss major medication decisions with your healthcare provider.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations and Context\u003c\/h2\u003e\n\u003cp\u003eIt is important to understand that this article is a \u003cstrong\u003econtroversial, invited opinion piece\u003c\/strong\u003e, not a new clinical trial. It represents the perspective of Dr. Paul J. Rosch, who has long been a critic of the cholesterol hypothesis and a champion of stress research. Many cardiologists, lipid specialists, and public health organizations strongly disagree with his conclusions. The preponderance of current guidelines still holds that elevated LDL cholesterol is a major, modifiable risk factor for heart disease, and that statins reduce cardiovascular events in specific high-risk populations. There is also abundant research showing that smoking cessation and blood pressure control dramatically reduce heart disease deaths—findings that are not disputed in this article.\u003c\/p\u003e\n\u003cp\u003eMoreover, the article was published in 2008. Since then, cholesterol science has evolved, and some of the author's specific arguments (such as his use of older trial data) may be debated. However, his core points about the weaknesses of the original cholesterol studies, the misleading nature of relative risk, and the importance of stress remain part of ongoing scientific discussion. Patients should view this article as a challenge to conventional thinking, not as a definitive reason to abandon cholesterol management.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eDoes cholesterol really cause heart disease?\u003c\/h3\u003e\n\u003cp\u003eThis article argues that cholesterol has not been proven to cause coronary heart disease. It notes that in the Framingham study, half of heart attacks occurred in people with normal or low cholesterol, and the MONICA project found no correlation between fat consumption or cholesterol levels and heart attack rates across 21 countries.\u003c\/p\u003e\n\u003ch3\u003eWhat is the difference between absolute and relative risk?\u003c\/h3\u003e\n\u003cp\u003eRelative risk compares the rate of events between two groups using a ratio, which can sound large. Absolute risk uses raw numbers. For example, a statin may be said to reduce heart attacks by 34%, but the absolute reduction is from 4.1% to 2.7%, meaning 71 people must take it daily for five years to prevent one attack.\u003c\/p\u003e\n\u003ch3\u003eWhat did the MRFIT trial actually find?\u003c\/h3\u003e\n\u003cp\u003eMRFIT screened 350,000 men and selected 12,866 at high risk. The intervention group cut dietary fat, cholesterol, and calories, and received treatment for hypertension and smoking. After ten years, there was no significant difference in total mortality compared to usual care, and death rates from hemorrhagic stroke, cancer, suicide, and violence increased.\u003c\/p\u003e\n\u003ch3\u003eCan stress really affect my heart?\u003c\/h3\u003e\n\u003cp\u003eYes, according to this article. Stress can increase homocysteine, C-reactive protein, and fibrinogen, which promote inflammation and clotting. It can cause coronary vasoconstriction, spasm, and platelet aggregation, increase visceral fat, and even produce myocardial necrosis. Type A behavior is described as being as significant a risk factor as high cholesterol, hypertension, or smoking.\u003c\/p\u003e\n\u003ch3\u003eShould I stop taking my cholesterol-lowering medication?\u003c\/h3\u003e\n\u003cp\u003eNo. This article is an opinion piece and not individual medical advice. Many cardiologists still believe that cholesterol-lowering drugs benefit high-risk patients. Do not change any medication without discussing it with your healthcare provider, who can assess your personal risk and treatment options.\u003c\/p\u003e\n\u003ch3\u003eWhy is the Seven Countries Study criticized?\u003c\/h3\u003e\n\u003cp\u003eThe Seven Countries Study claimed a straight-line relationship between saturated fat, cholesterol, and heart disease deaths. However, its author Ancel Keys had data from 22 countries but included only 7, leading to accusations of cherry-picking. A statistician called the diet assessment methodology highly inconsistent and thoroughly suspect, and Keys later admitted that diet cholesterol does not matter unless you are a chicken or a rabbit.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Cholesterol does not cause coronary heart disease in contrast to stress\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor:\u003c\/strong\u003e Paul J. Rosch, MD — Department of Medicine and Psychiatry, New York Medical College, Valhalla, New York, USA, and The American Institute of Stress, Yonkers, New York, USA\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e \u003cem\u003eScandinavian Cardiovascular Journal\u003c\/em\u003e, 2008, Vol. 42, No. 4, pages 244–249. DOI: 10.1080\/14017430801993701\u003c\/p\u003e\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research published in a medical journal. It has been written to make the original research accessible to patients and the general public. Always speak with your healthcare provider about your individual heart disease risk and treatment options.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47423013978268,"sku":null,"price":0.0,"currency_code":"JPY","in_stock":true}],"url":"https:\/\/diagnosticdetectives.jp\/products\/cholesterol-vs-stress-one-doctors-case-that-stress-not-cholesterol-is-the-real-heart-disease-driver","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}